Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia
Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoi...
Gespeichert in:
Veröffentlicht in: | Surgery 2017-10, Vol.162 (4), p.901-916 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 916 |
---|---|
container_issue | 4 |
container_start_page | 901 |
container_title | Surgery |
container_volume | 162 |
creator | Hasan, Shirin Mosier, Michael J. Szilagyi, Andrea Gamelli, Richard L. Muthumalaiappan, Kuzhali |
description | Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.
Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.
Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.
The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively. |
doi_str_mv | 10.1016/j.surg.2017.06.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1921130948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0039606017303902</els_id><sourcerecordid>1921130948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-4762110fb26827b2964163963d3b0b88026538c545d14bcad3120399bc5fc4273</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EoqVwARYoSzYJYztxEokNKr9SJTawthxn2rrkp9gJUq_FQTgTjlIQK1ajGb33NO8j5JxCRIGKq03keruKGNA0AhEB0AMypQlnYcoFPSRTAJ6HAgRMyIlzGwDIY5odkwnLUio40Cl5uzVOW-ww-PoMVWmxQbsyOqhRr1VjXO0Ci6u-Ul6Byla7QDVlMK52161tu20NOuMC0_y9dKYJ7XDvVNN5D9ZGnZKjpaocnu3njLze373MH8PF88PT_GYR6higC-NUMEphWTCRsbRguYj9s7ngJS-gyDJgIuGZTuKkpHGhVckp80XzQidLHbOUz8jlmLu17XuPrpO1L4lV5d9oeydp7vO5Z5F5KRul2rbOWVzKrTW1sjtJQQ6Q5UYOkOUAWYKQHrI3Xezz-6LG8tfyQ9ULrkcB-pYfBq102mCjsTQWdSfL1vyX_w3thI9n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1921130948</pqid></control><display><type>article</type><title>Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect</source><creator>Hasan, Shirin ; Mosier, Michael J. ; Szilagyi, Andrea ; Gamelli, Richard L. ; Muthumalaiappan, Kuzhali</creator><creatorcontrib>Hasan, Shirin ; Mosier, Michael J. ; Szilagyi, Andrea ; Gamelli, Richard L. ; Muthumalaiappan, Kuzhali</creatorcontrib><description>Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.
Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.
Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.
The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/j.surg.2017.06.001</identifier><identifier>PMID: 28716301</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenergic Antagonists - pharmacology ; Anemia - etiology ; Animals ; Burns - complications ; Butoxamine - pharmacology ; Disease Models, Animal ; Erythropoiesis ; Male ; Mice ; Nadolol - pharmacology ; Propanolamines - pharmacology ; Propranolol - pharmacology ; Receptors, Adrenergic, beta - drug effects ; Receptors, Adrenergic, beta - physiology</subject><ispartof>Surgery, 2017-10, Vol.162 (4), p.901-916</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-4762110fb26827b2964163963d3b0b88026538c545d14bcad3120399bc5fc4273</citedby><cites>FETCH-LOGICAL-c400t-4762110fb26827b2964163963d3b0b88026538c545d14bcad3120399bc5fc4273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.surg.2017.06.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28716301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasan, Shirin</creatorcontrib><creatorcontrib>Mosier, Michael J.</creatorcontrib><creatorcontrib>Szilagyi, Andrea</creatorcontrib><creatorcontrib>Gamelli, Richard L.</creatorcontrib><creatorcontrib>Muthumalaiappan, Kuzhali</creatorcontrib><title>Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.
Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.
Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.
The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.</description><subject>Adrenergic Antagonists - pharmacology</subject><subject>Anemia - etiology</subject><subject>Animals</subject><subject>Burns - complications</subject><subject>Butoxamine - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Erythropoiesis</subject><subject>Male</subject><subject>Mice</subject><subject>Nadolol - pharmacology</subject><subject>Propanolamines - pharmacology</subject><subject>Propranolol - pharmacology</subject><subject>Receptors, Adrenergic, beta - drug effects</subject><subject>Receptors, Adrenergic, beta - physiology</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1OwzAQhS0EoqVwARYoSzYJYztxEokNKr9SJTawthxn2rrkp9gJUq_FQTgTjlIQK1ajGb33NO8j5JxCRIGKq03keruKGNA0AhEB0AMypQlnYcoFPSRTAJ6HAgRMyIlzGwDIY5odkwnLUio40Cl5uzVOW-ww-PoMVWmxQbsyOqhRr1VjXO0Ci6u-Ul6Byla7QDVlMK52161tu20NOuMC0_y9dKYJ7XDvVNN5D9ZGnZKjpaocnu3njLze373MH8PF88PT_GYR6higC-NUMEphWTCRsbRguYj9s7ngJS-gyDJgIuGZTuKkpHGhVckp80XzQidLHbOUz8jlmLu17XuPrpO1L4lV5d9oeydp7vO5Z5F5KRul2rbOWVzKrTW1sjtJQQ6Q5UYOkOUAWYKQHrI3Xezz-6LG8tfyQ9ULrkcB-pYfBq102mCjsTQWdSfL1vyX_w3thI9n</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Hasan, Shirin</creator><creator>Mosier, Michael J.</creator><creator>Szilagyi, Andrea</creator><creator>Gamelli, Richard L.</creator><creator>Muthumalaiappan, Kuzhali</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia</title><author>Hasan, Shirin ; Mosier, Michael J. ; Szilagyi, Andrea ; Gamelli, Richard L. ; Muthumalaiappan, Kuzhali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-4762110fb26827b2964163963d3b0b88026538c545d14bcad3120399bc5fc4273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenergic Antagonists - pharmacology</topic><topic>Anemia - etiology</topic><topic>Animals</topic><topic>Burns - complications</topic><topic>Butoxamine - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Erythropoiesis</topic><topic>Male</topic><topic>Mice</topic><topic>Nadolol - pharmacology</topic><topic>Propanolamines - pharmacology</topic><topic>Propranolol - pharmacology</topic><topic>Receptors, Adrenergic, beta - drug effects</topic><topic>Receptors, Adrenergic, beta - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasan, Shirin</creatorcontrib><creatorcontrib>Mosier, Michael J.</creatorcontrib><creatorcontrib>Szilagyi, Andrea</creatorcontrib><creatorcontrib>Gamelli, Richard L.</creatorcontrib><creatorcontrib>Muthumalaiappan, Kuzhali</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasan, Shirin</au><au>Mosier, Michael J.</au><au>Szilagyi, Andrea</au><au>Gamelli, Richard L.</au><au>Muthumalaiappan, Kuzhali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>2017-10</date><risdate>2017</risdate><volume>162</volume><issue>4</issue><spage>901</spage><epage>916</epage><pages>901-916</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><abstract>Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.
Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.
Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.
The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28716301</pmid><doi>10.1016/j.surg.2017.06.001</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0039-6060 |
ispartof | Surgery, 2017-10, Vol.162 (4), p.901-916 |
issn | 0039-6060 1532-7361 |
language | eng |
recordid | cdi_proquest_miscellaneous_1921130948 |
source | MEDLINE; Elsevier ScienceDirect |
subjects | Adrenergic Antagonists - pharmacology Anemia - etiology Animals Burns - complications Butoxamine - pharmacology Disease Models, Animal Erythropoiesis Male Mice Nadolol - pharmacology Propanolamines - pharmacology Propranolol - pharmacology Receptors, Adrenergic, beta - drug effects Receptors, Adrenergic, beta - physiology |
title | Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T05%3A58%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discrete%20%CE%B2-adrenergic%20mechanisms%20regulate%20early%20and%20late%20erythropoiesis%20in%20erythropoietin-resistant%20anemia&rft.jtitle=Surgery&rft.au=Hasan,%20Shirin&rft.date=2017-10&rft.volume=162&rft.issue=4&rft.spage=901&rft.epage=916&rft.pages=901-916&rft.issn=0039-6060&rft.eissn=1532-7361&rft_id=info:doi/10.1016/j.surg.2017.06.001&rft_dat=%3Cproquest_cross%3E1921130948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1921130948&rft_id=info:pmid/28716301&rft_els_id=S0039606017303902&rfr_iscdi=true |